Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medclair ABNGM:MCLR -2.24%67 FCF Margin % is -31.03% as of Mar. 2026. GuruFocus rates NGM:MCLR with a GF Score™ of 67/100 and a GF Value™ of kr2.35 (Modestly Overvalued). Among 816 Medical Devices & Instruments companies, Medclair AB ranks worse than 54.29% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Medclair AB's Free Cash Flow for the
three
months ended in Mar. 2026 was kr-5.66 Mil. Medclair AB's Revenue for the
three
months ended in Mar. 2026 was kr18.24 Mil. Therefore, Medclair AB's FCF Margin % for the quarter that ended in Mar. 2026 was -31.03%.
The historical rank and industry rank for Medclair AB's FCF Margin % or its related term are showing as below:
NGM:MCLR'
s FCF Margin % Range Over the Past 10 Years
Min: -144.76 Med: -23.61 Max: 4.03
Current: -2.03
During the past 11 years, the highest FCF Margin % of Medclair AB was 4.03%. The lowest was -144.76%. And the median was -23.61%.
NGM:MCLR's FCF Margin % is ranked worse than 54.29% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: -0.57
vs NGM:MCLR: -2.03
Medclair AB FCF Margin % Related Terms
Medclair AB FCF Margin % Historical Data
* Premium members only.
The historical data trend for Medclair AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:MCLR vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, Medclair AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Medclair AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medclair AB (NGM:MCLR) has a FCF Margin % of -31.03% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medclair AB and its competitors. According to the industry distribution chart, Medclair AB ranks #443 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 54.3%.
Is Medclair AB's FCF Margin % too high?
Medclair AB's current FCF Margin % is -31.03%. Based on the distribution chart, Medclair AB ranks #443 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medclair AB has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medclair AB ranks #443 out of 816 companies for FCF Margin %. This places Medclair AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medclair AB and its competitors. Medclair AB's current FCF Margin % is -31.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.35, compared to a current price of kr3.05 — trading 29.8% above its estimated fair value. The current FCF Margin % is -31.03%. Medclair AB's overall GF Score™ is 67/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current FCF Margin % is -31.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr3.05 is trading 29.8% above its estimated GF Value™ of kr2.35.
GuruFocus considers Medclair AB to be Modestly Overvalued.
Key valuation signals for NGM:MCLR:
FCF Margin %: -31.03%
GF Value™: kr2.35 vs. price of kr3.05 (29.8% above fair value)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
67GF Score
Get the complete analysis for NGM:MCLR
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
